GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Net Income From Continuing Operations

Cantargia AB (OSTO:CANTA) Net Income From Continuing Operations : kr-171.96 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cantargia AB's net income from continuing operations for the three months ended in Mar. 2025 was kr-45.03 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was kr-171.96 Mil.

Cantargia AB Net Income From Continuing Operations Historical Data

The historical data trend for Cantargia AB's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Net Income From Continuing Operations Chart

Cantargia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -173.95 -370.27 -381.55 -290.02 -168.58

Cantargia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.66 -43.83 -42.41 -40.69 -45.03

Cantargia AB Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-171.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Net Income From Continuing Operations
Comparable Companies
OSTO:ACE OSTO:IRLAB A OSTO:ONCO OSTO:XBRANE OSTO:IVACC OSTO:ELIC OSTO:LIPUM OSTO:GUARD OSTO:XINT XSAT:CESSA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
7V3:Germany
Address
Scheelevagen 27, Lund, SWE, 223 63
Website
https://www.cantargia.com
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, as well as its antibody platform CANxx.

Cantargia AB Headlines

No Headlines